Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

(2020) Andrew N Phillips et al.   Lancet HIV

Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort

(2020) Nicolò Girometti et al.   HIV MEDICINE

Sexually Transmitted Infections and Human Immunodeficiency Virus

(2020) Robin M. Lawson   NURSING CLINICS OF NORTH AMERICA

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

(2020) Willem D F Venter et al.   Lancet HIV

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

(2020) Alexandra Calmy et al.   Lancet HIV

Comparative effectiveness of first-line antiretroviral therapy

(2019) Mariana Veloso Meireles et al.   AIDS

A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients

(2019) Ryosaku Ota et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis

(2019) Mario Cruciani et al.   PLoS One

Benefits and risks of rapid initiation of antiretroviral therapy

(2018) Nathan Ford et al.   AIDS

Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis

(2017) Steve Kanters et al.   Lancet HIV

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review

(2016) George W. Rutherford et al.   PLoS One

Brief Report

(2015) Sharon Walmsley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

(2015) Christopher Kandel et al.   Drug Design Development and Therapy

Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection

(2014) R. Chris Rathbun et al.   ANNALS OF PHARMACOTHERAPY

Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up

(2014) Frederick J. Lee et al.   PLoS One

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES